FDA approves Blenrep for relapsed or refractory multiple myeloma

Published Date: 31 Oct 2025

The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

FDA Approves New Drug Combo for RR Multiple Myeloma

3.

November 2023, Medical Bulletin 04/.

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

FDA approves Blenrep for relapsed or refractory multiple myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot